Anxiety

Kaya Enters Jamaica’s Legal Psilocybin Market

Retrieved on: 
Wednesday, January 11, 2023

KINGSTON, Jamaica and LOS ANGELES, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Kaya Group ("Kaya" or "the Company") (OTC: NUGL), the first medicinal Ganja herb house in the Caribbean and holistic, wellness-focused ecosystem, announced today its Kaya Extracts subsidiary plans to enter the legal psilocybin market in Jamaica where the laws are relaxed, targeting the multibillion-dollar industry for the development, marketing and distribution of psilocybin mushrooms.

Key Points: 
  • KINGSTON, Jamaica and LOS ANGELES, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Kaya Group ("Kaya" or "the Company") (OTC: NUGL), the first medicinal Ganja herb house in the Caribbean and holistic, wellness-focused ecosystem, announced today its Kaya Extracts subsidiary plans to enter the legal psilocybin market in Jamaica where the laws are relaxed, targeting the multibillion-dollar industry for the development, marketing and distribution of psilocybin mushrooms.
  • This will include Kaya's current rollout of traditional Jamaica Psilocybin Mushroom and Capsules at its Herbhouse locations in Falmouth, Ocho Rios, and Kingston.
  • The first milestone includes developing and launching our nutraceuticals' range of psilocybin concentrations from micro-doses to hallucinogenic levels of dosing.
  • As a leader in the plant-based wellness industry, Kaya is committed to providing high-quality, responsibly sourced psilocybin products.

National Nonprofit Can’d Aid Serves 85,000 People With Over 100 Local Community Events In 2022

Retrieved on: 
Wednesday, January 11, 2023

Can’d Aid hosted more than 100 projects across the US in 2022 that supported sustainability, disaster relief, and physical health and mental wellness.

Key Points: 
  • Can’d Aid hosted more than 100 projects across the US in 2022 that supported sustainability, disaster relief, and physical health and mental wellness.
  • This year, with the help of 6,000 volunteers and generous corporate sponsors, Can’d Aid was able to serve more than 85,000 people.
  • Since Can’d Aid’s inception in 2013, the nonprofit has built and donated thousands of bikes and skateboards through its Treads + Trails program.
  • Thanks to ongoing fundraising efforts, corporate partnerships, and continued community engagement, Can’d Aid donated 45% more bikes and skateboards year-over-year in 2022.

Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer

Retrieved on: 
Tuesday, January 10, 2023

MIAMI, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery technologies for the next generation of mental health treatments, today announced that Dr. Julian Bailes has accepted the role of Chief Medical Officer and will also join the company’s Board of Directors.

Key Points: 
  • MIAMI, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery technologies for the next generation of mental health treatments, today announced that Dr. Julian Bailes has accepted the role of Chief Medical Officer and will also join the company’s Board of Directors.
  • Bailes is an esteemed leader in the fields of neurosurgery and traumatic brain injuries.
  • His expertise in the understanding of CTE was showcased in the 2015 film “Concussion,” starring Will Smith, where Bailes was portrayed by actor Alec Baldwin.
  • The Medical Advisory Board works in tandem with the company’s scientific team in identifying and reviewing outstanding molecules to bring through the drug discovery and development process to clinical application.

Heart to Heart CPR Raises Awareness of Ontario's NEW Workplace Naloxone Requirements Effective June 1, 2023

Retrieved on: 
Tuesday, January 10, 2023

For up to two years, Ontario will provide one free nasal spray naloxone kit per workplace and free naloxone training for up to two workers per workplace.

Key Points: 
  • For up to two years, Ontario will provide one free nasal spray naloxone kit per workplace and free naloxone training for up to two workers per workplace.
  • Training requirements must include how to recognize opioid poisoning, how to administer naloxone , and being acquainted with any hazards related to the administration of naloxone .
  • Oftentimes naloxone alone is not enough to assist a worker who is unconscious and experiencing opioid poisoning in the workplace.
  • To conclude, not all employers have to comply with the OHSA requirements to provide naloxone in the workplace.

atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917

Retrieved on: 
Monday, January 9, 2023

GRX-917 was well tolerated with sedation comparable to placebo noted over the entirety of the dose range explored.

Key Points: 
  • GRX-917 was well tolerated with sedation comparable to placebo noted over the entirety of the dose range explored.
  • Initiation of a GRX-917 efficacy study is anticipated in H1 2023 with results expected in 2024.
  • NEW YORK and BERLIN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day.
  • The randomized, double-blind, placebo-controlled trial was designed to evaluate the safety, tolerability, and pharmacokinetic profile of single and multiple ascending doses of orally administered GRX-917.

Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104

Retrieved on: 
Monday, January 9, 2023

RE104 is a proprietary, novel serotonergic psychedelic compound that Reunion is developing as a potential fast-acting and durable treatment for patients suffering from postpartum depression and other mental health conditions.

Key Points: 
  • RE104 is a proprietary, novel serotonergic psychedelic compound that Reunion is developing as a potential fast-acting and durable treatment for patients suffering from postpartum depression and other mental health conditions.
  • In this first-in-human, Phase 1 study, RE104 was shown to be safe and well tolerated, with no serious or severe adverse events.
  • The interim analysis included 32 healthy volunteers across four ascending dose cohorts, with two of the eight subjects in each cohort receiving placebo.
  • While completing the preplanned interim analysis, and per the recommendation of the Safety Review Committee (SRC), Reunion has continued with dose escalation and initiated a fifth cohort.

The United States Nicotine Industry is Projected to Reach $110.6 Billion by 2027 - Shift Towards Next Generation Products Fuels the Market - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023

The US nicotine market in 2021 was valued at US$84.78 billion.

Key Points: 
  • The US nicotine market in 2021 was valued at US$84.78 billion.
  • The market value is projected to reach US$110.63 billion by 2027.
  • Furthermore, the US nicotine market by volume is anticipated to reach 18.50 billion pieces in 2027.
  • People started consuming nicotine through next generation products such as vaping and heated tobacco products.

Vida Health Makes Two Additions to Executive Leadership Team

Retrieved on: 
Monday, January 9, 2023

Virtual cardiometabolic care leader Vida Health today announced the additions of Elaine Divelbliss and Andrew Webb to its executive leadership team.

Key Points: 
  • Virtual cardiometabolic care leader Vida Health today announced the additions of Elaine Divelbliss and Andrew Webb to its executive leadership team.
  • View the full release here: https://www.businesswire.com/news/home/20230109005207/en/
    Elaine Divelbliss and Andrew Webb join Vida Health’s executive leadership team as Chief People Officer & General Counsel and Chief Financial Officer respectively.
  • (Photo: Business Wire)
    “We’re thrilled to have Elaine and Andrew bring their wealth of knowledge and experience to Vida’s leadership team,” said Vida Health Founder and CEO Stephanie Tilenius.
  • “Stephanie and the Vida team have built an amazing product that leads to truly life-changing outcomes for its members.

INTRODUCING THE MEADOWS OUTPATIENT CENTER-DENVER

Retrieved on: 
Tuesday, January 10, 2023

PHOENIX, Jan. 10, 2023 /PRNewswire/ -- Meadows Behavioral Healthcare (MBH), the industry leader in trauma, addiction, eating disorders, and co-occurring disorder treatment for more than 45 years, is excited to announce the grand opening of The Meadows Outpatient Center-Denver. Located in the city's Denver Tech Center, this new state-of-the-art facility is currently accepting patients and will begin offering treatment to Colorado residents on January 23, 2023.

Key Points: 
  • Industry leader Meadows Behavioral Healthcare announces the opening of The Meadows Outpatient Center-Denver.
  • The Meadows Outpatient Center-Denver will offer both intensive outpatient and partial hospitalization programs, featuring an on-site Brain Center to provide neurofeedback and other self-regulation techniques.
  • "Our Meadows Model combined with time-tested substance use disorder outpatient treatment works incredibly well, and our patients in recovery and our outcomes prove that."
  • "I've seen the power of the Meadows Model to change lives," says Sean Walsh, CEO of Meadows Behavioral Healthcare.

OxiWear Signs Letter of Intent with the Inspired Performance Institute

Retrieved on: 
Tuesday, January 10, 2023

ARLINGTON, Va., Jan. 10, 2023 /PRNewswire/ -- OxiWear signed a letter of intent with the Inspired Performance Institute based in Lake Nona, Florida. OxiWear will work with the Inspired Performance Institute to develop a custom application to use along with the OxiWear device to help individuals manage and pro-actively prevent panic attack episodes.

Key Points: 
  • ARLINGTON, Va., Jan. 10, 2023 /PRNewswire/ -- OxiWear signed a letter of intent with the Inspired Performance Institute based in Lake Nona, Florida.
  • OxiWear will work with the Inspired Performance Institute to develop a custom application to use along with the OxiWear device to help individuals manage and pro-actively prevent panic attack episodes.
  • "Our team at the Inspired Performance Institute found a natural partnership in OxiWear because of our shared commitment to allow people to live their most stable and successful lives," said Dr. Don Wood, founder and CEO of the Inspired Performance Institute.
  • The Inspired Performance Institute exemplifies this in their mission," stated Shavini Fernando, Founder and CEO, OxiWear.